miR-155 was reported to activate PI3K/AKT signaling pathway in DLBCL and CLL through targeting SH2-containing inositol phosphatase-1 (SHIP-1) (171, 172). This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.